Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) Return on Capital Employed: 2017-2025

Historic Return on Capital Employed for Akebia Therapeutics (AKBA) over the last 8 years, with Sep 2025 value amounting to 0.08%.

  • Akebia Therapeutics' Return on Capital Employed rose 32.00% to 0.08% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.08%, marking a year-over-year increase of 32.00%. This contributed to the annual value of -0.34% for FY2024, which is 10.00% down from last year.
  • According to the latest figures from Q3 2025, Akebia Therapeutics' Return on Capital Employed is 0.08%, which was up 2,018.57% from 0.00% recorded in Q2 2025.
  • Akebia Therapeutics' Return on Capital Employed's 5-year high stood at 0.08% during Q3 2025, with a 5-year trough of -0.94% in Q1 2022.
  • Moreover, its 3-year median value for Return on Capital Employed was -0.24% (2024), whereas its average is -0.23%.
  • As far as peak fluctuations go, Akebia Therapeutics' Return on Capital Employed slumped by 35bps in 2021, and later soared by 73bps in 2023.
  • Over the past 5 years, Akebia Therapeutics' Return on Capital Employed (Quarterly) stood at -0.87% in 2021, then soared by 57bps to -0.30% in 2022, then fell by 4bps to -0.33% in 2023, then declined by 5bps to -0.38% in 2024, then surged by 32bps to 0.08% in 2025.
  • Its Return on Capital Employed was 0.08% in Q3 2025, compared to 0.00% in Q2 2025 and -0.13% in Q1 2025.